Article Text

Download PDFPDF

4CPS-088 Effectiveness of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C
  1. C Burgui1,
  2. R Juanbeltz2,
  3. J Castilla2,
  4. B Larrayoz3,
  5. M Sarobe3,
  6. JM Zozaya4,
  7. M Gracia-Ruiz de Alda5,
  8. R San Miguel3
  1. 1Ciber Epidemiologia y Salud Publica Ciberesp, Hospital Pharmacy, Pamplona, Spain
  2. 2Instituto de Salud Publica de Navarra-Idisna- Ciber Epidemiología y Salud Pública Ciberesp, Transmissible Disease and Vaccination, Pamplona, Spain
  3. 3Navarra Hospital Complex-Idisna, Hospital Pharmacy, Pamplona, Spain
  4. 4Navarra Hospital Complex-Idisna, Gastroenterology and Hepatology, Pamplona, Spain
  5. 5Navarra Hospital Complex, Infectious Disease, Pamplona, Spain


Background The availability of new pangenotypic direct-acting antiviral (DAA) combinations has simplified the treatment of chronic hepatitis C. Clinical trials have shown high rates of sustained virological response (SVR), but there is a paucity of data in a real-life context.

Purpose To assess the effectiveness of glecaprevir/pibrentasvir (GLE/PIB), a pangenotypic DAA combination, for the treatment of hepatitis C virus (HCV) infection.

Material and methods A retrospective observational study for patients treated with GLE/PIB between November 2017 and April 2018 in a reference hospital. Variables analysed: sex, age, genotype, previous HCV therapy, HIV co-infection, METAVIR score (F0-F4) and DAA treatment duration. Effectiveness was evaluated as SVR12, defined as HCV-RNA titres<15 IU/mL 12 weeks after the end of treatment (post12). Data were collected from medical records and the database of drug dispensation by hospital pharmacists.

Results One-hundred and one patients were included (59% men). Median age was 51 years (22–74). HCV genotypes: 30% G1a; 19% G1b; 1% G1 no-subtyped; 4% G2; and 28% G3 and 18% G4. Eleven patients had failed prior treatment (10 with interferon therapy and one with sofosbuvir/ledipasvir). Twenty-six per cent of patients were HIV co-infected. Fibrosis grade was 12% F4; 10% F3; 20% F2; and 58% F0–F1. Patients were treated for 8 weeks (n=88) or 12 weeks (n=13). At the end of treatment one patient had positive viral load (VL) (G3, naïve, F2, monoinfected, 8 weeks of treatment). At post12, data on VL was available in 91 patients. Eighty-nine patients have eliminated HCV infection and two rebounded (G3, naïve, F0, monoinfected, 8 weeks of treatment and G2, naïve, F0, co-infected, 8 weeks of treatment). Ten patients had not yet had their VL analysed (three were lost to follow-up and seven will be available soon). Per protocol analysis, the rate of SVR was 97% (95% CI, 94 to 100), 97% in monoinfected vs 96% in co-infected patients. The most common adverse events were fatigue and headache, although treatment was well tolerated (85% any adverse event).

Conclusion The combination GLE/PIB was effective with a high SVR12 rate, 97%. Co-infected and monoinfected patients had a similar response with an optimal safety profile.

References and/or acknowledgements EIPT-VHC project funded by the Spanish Ministry of Health and Carlos III Institute of Health.

No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.